Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

2.

Inconclusive BRCA Results Linked to Higher BC Risk

3.

TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL

4.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

5.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot